The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 19, 2020

Filed:

Nov. 19, 2015
Applicant:

Bristol-myers Squibb Company, Princeton, NJ (US);

Inventors:

Nils Lonberg, Woodside, CA (US);

Alan J. Korman, Piedmont, CA (US);

Mark J. Selby, San Francisco, CA (US);

Bryan C. Barnhart, Philadelphia, PA (US);

Aaron P. Yamniuk, Lawrenceville, NJ (US);

Mohan Srinivasan, Cupertino, CA (US);

Karla A. Henning, Milpitas, CA (US);

Michelle Minhua Han, Piedmont, CA (US);

Ming Lei, Princeton, NJ (US);

Liang Schweizer, Shanghai, CN;

Sandra V. Hatcher, Hillsborough, NJ (US);

Arvind Rajpal, San Francisco, CA (US);

Assignee:

BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 47/68 (2017.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6803 (2017.08); A61K 39/3955 (2013.01); C07K 16/00 (2013.01); C07K 16/2878 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/53 (2013.01); C07K 2317/71 (2013.01); C07K 2317/72 (2013.01); C07K 2317/75 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01);
Abstract

Provided herein are heavy chain constant regions (referred to as 'modified heavy chain constant regions'), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.


Find Patent Forward Citations

Loading…